Header Logo

Connection

Debra Richardson to Ovarian Neoplasms

Back to Details
This is a "connection" page, showing publications Debra Richardson has written about Ovarian Neoplasms.
Debra Richardson
Connection Strength
6.380
Ovarian Neoplasms
  1. A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025 Aug; 199:96-102.
    View in: PubMed
    Score: 0.617
  2. A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers. Cancer. 2025 Jan 01; 131(1):e35680.
    View in: PubMed
    Score: 0.596
  3. The emerging use of antibody-drug conjugates in ovarian cancer. Clin Adv Hematol Oncol. 2023 05; 21(5):244-246.
    View in: PubMed
    Score: 0.531
  4. Is there a role for secondary debulking in ovarian cancer? A review of the current literature. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):1-5.
    View in: PubMed
    Score: 0.511
  5. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022 08; 166(2):219-229.
    View in: PubMed
    Score: 0.499
  6. Should we or should we not? Secondary debulking in ovarian cancer. Lancet Oncol. 2021 04; 22(4):412-413.
    View in: PubMed
    Score: 0.458
  7. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):1057-1071.
    View in: PubMed
    Score: 0.387
  8. Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299.
    View in: PubMed
    Score: 0.384
  9. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.
    View in: PubMed
    Score: 0.369
  10. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
    View in: PubMed
    Score: 0.193
  11. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol. 2008 Nov; 111(2):233-6.
    View in: PubMed
    Score: 0.192
  12. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006 Nov; 103(2):667-72.
    View in: PubMed
    Score: 0.165
  13. Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer. 2025 Mar 18; 25(1):500.
    View in: PubMed
    Score: 0.151
  14. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Mar 13; 13(3).
    View in: PubMed
    Score: 0.151
  15. First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Jan 11; 13(1).
    View in: PubMed
    Score: 0.149
  16. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer. 2023 09 04; 33(9):1458-1463.
    View in: PubMed
    Score: 0.136
  17. Advances in antibody-drug conjugates for gynecologic malignancies. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):6-14.
    View in: PubMed
    Score: 0.129
  18. Olaparib in the treatment of ovarian cancer. Future Oncol. 2019 Oct; 15(30):3435-3449.
    View in: PubMed
    Score: 0.103
  19. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
    View in: PubMed
    Score: 0.089
  20. Ovarian involvement in endometrioid adenocarcinoma of uterus. Gynecol Oncol. 2015 Sep; 138(3):532-5.
    View in: PubMed
    Score: 0.077
  21. Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecol Oncol. 2014 Sep; 134(3):552-5.
    View in: PubMed
    Score: 0.072
  22. Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. Gynecol Oncol. 2014 Jul; 134(1):84-9.
    View in: PubMed
    Score: 0.071
  23. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
    View in: PubMed
    Score: 0.067
  24. Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer. Clin Obstet Gynecol. 2012 Mar; 55(1):131-55.
    View in: PubMed
    Score: 0.061
  25. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010 Oct; 20(7):1125-31.
    View in: PubMed
    Score: 0.056
  26. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer. 2009 Oct; 19(7):1195-8.
    View in: PubMed
    Score: 0.052
  27. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009 Jan; 113(1):11-17.
    View in: PubMed
    Score: 0.049
  28. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009 Jan; 112(1):55-9.
    View in: PubMed
    Score: 0.049
  29. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.